Analyst Price Targets — CSTL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 3, 2026 10:10 am | Sung Ji Nam | BTIG | $44.00 | $28.00 | StreetInsider | Castle Biosciences (CSTL) PT Raised to $44 at BTIG |
| July 31, 2026 11:15 am | — | Robert W. Baird | $36.00 | $26.79 | TheFly | Castle Biosciences price target lowered to $36 from $43 at Baird |
| June 24, 2026 8:26 pm | — | Roth Capital | $40.00 | $22.12 | TheFly | Castle Biosciences initiated with a Buy at Roth Capital |
| May 29, 2026 2:33 pm | — | KeyBanc | $35.00 | $21.19 | TheFly | Castle Biosciences price target lowered to $35 from $50 at KeyBanc |
| April 20, 2026 1:00 pm | Kyle Mikson | Canaccord Genuity | $40.00 | $25.04 | TheFly | Castle Biosciences price target lowered to $40 from $50 at Canaccord |
| January 29, 2026 8:40 pm | Paul Knight | KeyBanc | $50.00 | $39.16 | TheFly | Castle Biosciences price target raised to $50 from $36 at KeyBanc |
| January 26, 2026 2:35 pm | Subbu Nambi | Guggenheim | $47.00 | $43.08 | TheFly | Castle Biosciences price target raised to $47 from $43 at Guggenheim |
| January 12, 2026 2:17 pm | — | Lake Street | $52.00 | $40.14 | TheFly | Castle Biosciences price target raised to $52 from $35 at Lake Street |
| January 5, 2026 2:26 pm | — | Guggenheim | $43.00 | $37.77 | TheFly | Castle Biosciences price target raised to $43 from $30 at Guggenheim |
| December 22, 2025 11:54 am | — | Canaccord Genuity | $50.00 | $39.44 | TheFly | Castle Biosciences price target raised to $50 from $37 at Canaccord |
Latest News for CSTL
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m.
FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary listing on The Nasdaq Global Market, and its common stock is expected to begin…
Castle Biosciences NASDAQ: CSTL reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its reported beat, according to CFO Frank Stokes.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CSTL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.